Shares of the clinical-stage biopharma Biohaven (NYSE: BHVN) rocketed higher by 33.5% over the first four days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain was sparked by the company's research and development day presentation held on Wednesday. 

Highlights from Biohaven's presentation include the unexpected Food and Drug Administration (FDA) regulatory filing for the experimental spinocerebellar ataxia type 3 drug troriluzole, status updates on its closely watched epilepsy program, and a clinical strategy overview for its newly acquired neuroinflammatory asset BHV-8000.

Biohaven has kept a relatively low profile since selling its migraine headache assets to , and subsequently spinning off its remaining clinical pipeline as a stand-alone company in 2022. This R presentation, however, shows that the company has been extremely busy in the interim advancing multiple potential value drivers in the clinic. 

Continue reading

Source Fool.com